Safety And Efficacy Of Vaginal Misoprostol In Treatment Of First Trimester Miscarriage
DOI:
https://doi.org/10.14738/assrj.73.7914Abstract
Objective: This study was conducted to determine the outcome of medical treatment with vaginal misoprostol in missed miscarriage.
Methods: A randomized controlled study was performed in Benha Teaching Hospital between April 2016 and June 2017. Eighty patients diagnosed with miscarriage before 13 weeks of gestation and wanted to try medical treatment were included. A detailed ultrasound scan was performed to confirm the diagnosis. Patients took 400 microgram (mcg) of misoprostol vaginal as an initial dose, and repeated the same dose 4-6 hours apart. Successful medical abortion was defined as spontaneous expulsion of gestational products (including gestational sac, embryo, fetus, and placenta). Ultrasonography at least 24 hours later from the initial dose to assess the uterine cavity if gestational products were not expelled, surgical evacuation was performed.
Results: About two-thirds of patients (77.5%) had a successful outcome. The median interval time from pill to expulsion was 18 hours in the successful medical treatment group.
Conclusion: Medical treatment with vaginal misoprostol should be a proper option for the first trimester miscarriage, especially for the patient who want to avoid surgical procedure. We can reduce the unnecessary sedation or surgical intervention in the patients with the first trimester miscarriage.
References
Hurt KJ, Guile MW, Bienstock JL, Fox HE and Wallach EE. The Johns Hopkins manual of gynecology and th obstetrics. 4 ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2011.
National Collaborating Centre for Women's and Child-dren's Health (GB); National Institute for Health and Clinical Excellence (GB); Royal College of Obstetricians and Gynaecologists (GB).Ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. London (GB): Royal College of Obstetricians and Gynaecologists; 2012.
Francis O. An analysis of 1150 cases of abortions from the government R.S.R.M. Lying – in Hospital, Madras. J Obstet Gynaecol. India 1959, 10 : 62 – 70. th Cuningham FG. Williams Obstetrics. 24 ed. New York (NY): McGraw-Hill; 2014.
Olvier A, Overton C. Diagnosis and management of miscarriage. Practitioner 2014; 258 : 25 – 8, 23.
Kripke C. Expectant management vs. surgical treatment for miscarriage. Am Fam Physician 2006; 74 : 1125 – 6. Tuncalp O, Gulmezoglu AM and Souza JP. Surgical procedures for evacuating incomplete miscarriage. Cochrane Database Syst Rev 2010: CD001993.
Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 1997; 44 : 353 – 60.
Westhoffa C, Dasmahapatra R, Schaff E. Analgesica during at home use of misoprostol as part of a medical abortion regimen. Contraception 2000; 62 : 311-4.
Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wanger MS, Meyn LA, et al. mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion : randomized controlled trial. Obstet Gynecol. 2007; 109 : 885 – 94.
Kopp Kallner H, Fiala C, Gemzell – Danielsson K. Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion. Contraception 2012; 85 : 394 – 7. Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet 2013; 121 : 186-9.
Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997; 90 : 88 – 92.
Bracken H, Dabash R, Tsertsvadze G, Posohova S, Shah M, Hajri S, et al. A two – pill sublingual misoprostol out – patient regimen following mifepristone for medical abortion through 70 days' LMP : a prospective comparative open – label trial. Contraception 2014; 89 : 181 – 6.
Chong E, Tsereteli T, Nguyen NN, Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception 2012; 86 : 251 – 6.
Tang OS, Lau WN, Ng EH, Lee SW and Ho PC. A prospective randomized study to compare the use of repeated doses of vaginal with sublingual misoprostol in the management of first trimester silent miscarriages. Hum Reprod 2003; 18 : 176 – 81.
Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medial abortion. Contraception 2001; 64 : 81 – 5.
Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod 2004; 19 : 81 – 4.
Tang OS, Lau WN, Chan CC and Ho PC (2004): A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004; 111 : 1001–5.
Kulier R, Kapp N, Gulmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2011: CD002855.
Emarah, M. S. A. (2020). Safety And Efficacy Of Vaginal Misoprostol In Treatment Of First Trimester Miscarriage. Advances in Social Sciences rd Cunningham FG. Williams obstetrics. 23 ed. New York (NY): McGraw-Hill; 2010.
Bracken H; Family Planning Association of India (FPAI)/Gynuity Health Projects Research Group for Simplifying Medical Abortion in India. Home administration of miso-prostol for early medical abortion in India. Int J Gynaecol. Obstet 2010; 108 : 228 – 32.
Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Dan-ielsson K. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days. Hum Reprod 2010; 25 : 1153-7.24. Hofmyr GJ, Gulmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2010 : CD000941.
Hofmeyr GJ, Gulmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2010 : CD000941.
Gomez Ponce de Leon R, Wing D, Fiala C. Misoprostol for intrauterine fetal death. Int J Gynaecol Obstet 2007; 99 Suppl 2 : S190-3.
Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome – one century later. Fertil Steril 2008; 89 : 759 – 79.
Engelbrechtsen L, Langhoff – Roos J, Kjer JJ, Istre O. Placenta accreta : adherent placenta due to Asherman syndrome. Clin Case Rep 2015; 3 : 175 – 8. von Hertzen H, Baird D. Bellagio study and conference center. Frequently asked questions about medical abortion. Contraception 2006; 74 : 3 – 10.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Advances in Social Sciences Research Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
